News
Public · Published
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics reported positive results from Part A of its Phase 2 BELLA trial. In 95 patients with platinum-resistant ovarian cancer, Lifyorli combined with nab-paclitaxel and bevacizumab showed a median PFS, which means time without disease worsening, of 7.2 months.
Published:
Updated:
What happened
Corcept Therapeutics reported positive results from Part A of its Phase 2 BELLA trial. In 95 patients with platinum-resistant ovarian cancer, Lifyorli combined with nab-paclitaxel and bevacizumab showed a median PFS, which means time without disease worsening, of 7.2 months.
Confirmed
Global impact / market context
Longer time without disease worsening and higher response rates could make this three-drug combination a stronger treatment option for platinum-resistant ovarian cancer, a difficult-to-treat group. That could support future revenue for Corcept if later trials succeed and regulators approve the combination.
Analyst inference
The comparison uses results from BELLA and the separate Phase 3 ROSELLA study, not a single head-to-head trial. Investors may treat the improvements as encouraging but early, since final survival data had not been reached and Phase 2 results often differ from later-stage outcomes.
Analyst inference
What to watch
- Median overall survival had not been reached at the primary analysis. 88% of BELLA patients were alive at six months, versus 82% and 77% for the two ROSELLA comparison groups. Confirmed
- Watch whether Corcept announces a later-stage trial or regulatory discussions for Lifyorli in platinum-resistant ovarian cancer. Such steps would test whether these Phase 2 results hold in a larger, pivotal study. Proposed
- The strongest responses appeared in patients who had not previously received bevacizumab, with median PFS of 8.1 months and a 66% response rate. Future trial design may focus on this group, affecting costs and timelines. Analyst inference
Evidence
- Original source link unavailable